Join Us for a Special Investor Webinar with Genetic Technologies
Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE) is thrilled to invite investors to an exclusive webinar. This event will provide valuable insights into the company's pioneering efforts in genomics-focused health solutions.
What You Can Expect
In this engaging session, you'll hear from Genetic Technologies' senior leadership as they update you on the company's remarkable range of genomics-based tests, which concentrate on health, wellness, and critical diseases. They'll also discuss their innovative, capital-efficient model.
Discover the EasyDNA Platform
The EasyDNA platform is already making waves, with over $7 million in annual recurring revenue generated from the global paternity and health markets. With plans for significant expansion, Genetic Technologies is now offering more than 50 risk assessment tests across 14 categories, supported by an impressive 25 patents, with an additional nine pending.
Positioning for the Future
The predictive genomics market is on track for considerable growth, with projections indicating it will reach $4.6 billion by 2025, reflecting a strong annual growth rate of over 17%. The company has recently made organizational changes to optimize operating costs, focusing on maximizing sales and the commercialization of its advanced genomic technologies.
Interactive Q&A Session
An engaging live question and answer session will be a highlight of the event, allowing you to interact directly with management. This is a great chance to engage with industry leaders and gain deeper insights into the future direction of Genetic Technologies.
Registration Details
To secure your spot for this complimentary webinar, please head over to RedChip’s registration page. If you have questions in advance, feel free to submit them to ensure meaningful discussions during the live event.
About Genetic Technologies
Genetic Technologies Limited is a diverse molecular diagnostics company dedicated to enhancing global health outcomes through its well-known brands, geneType and EasyDNA. Their innovative cancer predictive testing and risk assessment tools empower healthcare professionals to provide improved solutions for patients around the world. Additionally, the company has developed a proprietary risk stratification platform over the past decade that integrates clinical and genetic risk data, yielding actionable insights for both physicians and patients.
Frequently Asked Questions
What is the focus of the upcoming webinar hosted by Genetic Technologies?
The webinar will provide insights into Genetic Technologies' genomics-based tests and recent developments within the company.
How can participants register for the webinar?
You can easily register for free through the RedChip registration page set up for the event.
What is the current revenue status of Genetic Technologies’ EasyDNA platform?
The EasyDNA platform currently boasts over $7 million in annual recurring revenue.
What is the expected growth of the predictive genomics market?
The predictive genomics market is projected to grow to $4.6 billion by 2025, with a compound annual growth rate exceeding 17%.
Who can attendees expect to hear from during the webinar?
Participants will hear engaging insights from the senior leadership team at Genetic Technologies, who will share valuable updates and perspectives.